Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 192 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Lupus Nephritis Phase 3 United States
Germany
France
India
Thailand
Spain
Colombia
China
Brazil
United Kingdom
Romania
Hungary
Korea, Republic of
Argentina
Italy
Guatemala
Vietnam
Taiwan
Lithuania
Malaysia
Hong Kong
Mexico
Canada
Czech Republic
Chile
Singapore
Estonia
View All

Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Primary Hypercholesterolemia, Mixed Dyslipidemia China

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Prostate Cancer Phase 2 Japan

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Non-Small Cell Lung Carcinoma Phase 4 India

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Glioblastoma Phase 1 United States
Spain
France
Switzerland
Portugal
View All

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Relapsing-Remitting Multiple Sclerosis Phase 4 United States
Canada

Characterizing the Use of Ofatumumab in a Real World Setting

Relapsing Multiple Sclerosis Australia

Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib

Breast Cancer Switzerland

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

Breast Cancer Phase 3 Spain
Denmark
Greece
Germany
Italy
France
Slovakia
Czech Republic
Belgium
Hungary
Poland
Canada
Portugal
Romania
Ireland
Finland
Bulgaria
View All

Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world

Breast Cancer India